{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/seborrhoeic-dermatitis/background-information/prevalence/","result":{"pageContext":{"chapter":{"id":"0f04315e-ba03-5be7-a5dc-c724c1e3fe90","slug":"prevalence","fullItemName":"Prevalence","depth":2,"htmlHeader":"<!-- begin field 7fb41763-0c2c-4dab-beaa-d7c3620c9ca1 --><h2>How common is it?</h2><!-- end field 7fb41763-0c2c-4dab-beaa-d7c3620c9ca1 -->","summary":"","htmlStringContent":"<!-- begin item f79d6d38-a83a-490d-b703-455e144b50d0 --><!-- begin field 01837e02-a570-4d47-ac1e-acc6116564ad --><ul><li>Seborrhoeic dermatitis is a common skin disorder — estimated prevalence varies from 1-5% in the general adult population.<ul><li>It is more common in men than in women.<ul><li>A comparative cross‐sectional study (n= 5498; 788 with seborrhoeic dermatitis) reporting on a prospective population‐based cohort of middle‐aged and elderly people found that men were twice as likely to have seborrhoeic dermatitis as women [adjusted OR 2·09, 95% CI 1·77–2·47] [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Sanders, 2018</a>].</li></ul></li></ul></li><li>Incidence is highest in infants younger than 3 months of age, during adolescence and in adults aged 30–60 years.<ul><li>Incidence of seborrhoeic dermatitis affecting the scalp (‘cradle cap’), the face, and nappy area in infants up to three months of age is reported to be up to 42% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Borda, 2015</a>].</li></ul></li><li>The prevalence of seborrhoeic dermatitis is higher in people with:<ul><li>HIV — reported prevalence varies widely from 17% to 83% in people with HIV or AIDS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Gary, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Clark, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Harada, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Wakelin, 2016</a>].</li><li>Chronic neurological conditions such as Parkinson's disease.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Bukvic Mokos et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Gary, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Kastarinen, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Ooi, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Borda, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Clark, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Hald, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Okokon, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">PCDS, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Ijaz, 2017</a>]</p><!-- end field 01837e02-a570-4d47-ac1e-acc6116564ad --><!-- end item f79d6d38-a83a-490d-b703-455e144b50d0 -->","topic":{"id":"b328d01a-a44a-57e1-8920-22321b4c6c8b","topicId":"67c69cb5-e030-443e-802f-758ce0fe90f8","topicName":"Seborrhoeic dermatitis","slug":"seborrhoeic-dermatitis","lastRevised":"Last revised in February 2019","chapters":[{"id":"2c32aabf-f751-57c2-9fb1-bfd7e4c7e58d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"96bfb0b4-09f0-5525-aaf3-ca2354a87cb4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9bf8c16e-f128-5c6a-b6e8-d4223dcf2346","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"debcdac6-7ef3-5820-90b8-353614354fc7","slug":"changes","fullItemName":"Changes"},{"id":"32308918-ad23-5b7d-a1c5-7c7a4edf3e35","slug":"update","fullItemName":"Update"}]},{"id":"efc69a37-1a91-539d-b4ce-b1cfc1d48baf","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"09ce3910-2aa3-537d-97db-f473bf3f3c99","slug":"goals","fullItemName":"Goals"},{"id":"37776aed-67d4-5001-8e82-0fec56ecaa71","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2638b372-65f4-549c-9c2d-fff4cf1c933d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"df03f868-28e0-52a9-9f30-aecfccaa745c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bf290438-2d1b-5233-a43a-e3fe0cbccaab","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d66aeca6-f9ff-5104-94d3-d115d20ad7d1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5f9559ed-2d1c-52f3-ae50-cb983d1b7c7c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"025302eb-268d-585c-b9a4-d83b4dbb0e5b","slug":"definition","fullItemName":"Definition"},{"id":"43d0a434-92b2-5c53-b4bd-f8ab32a8c0a3","slug":"causes","fullItemName":"Causes"},{"id":"0f04315e-ba03-5be7-a5dc-c724c1e3fe90","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ad49e37a-e725-5ad1-9e7b-f84a79627169","slug":"complications","fullItemName":"Complications"},{"id":"50cfb7dd-1ad7-5d22-9c7e-8472fb0af48c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"26dec6e1-8806-50b7-869d-1e010fa15e89","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1f674962-dade-5ce5-9b92-60820da005f7","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"f384b060-7f9e-593e-8a77-6bbf957fd0c4","slug":"assessment","fullItemName":"Assessment"},{"id":"2b98bc5c-ae88-522e-89c4-79e05d301c3f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"521d1a4a-9184-5872-ab66-2a3fed074cc8","fullItemName":"Management","slug":"management","subChapters":[{"id":"ca5edad5-d74c-565f-b254-2c59bed62420","slug":"seborrhoeic-dermatitis-infants","fullItemName":"Scenario: Seborrhoeic dermatitis - infants"},{"id":"4172af9c-8f8b-5bcc-a160-ca83f520099c","slug":"seborrhoeic-dermatitis-scalp-beard","fullItemName":"Scenario: Seborrhoeic dermatitis - scalp and beard"},{"id":"ad81b0ed-2e0c-5a1d-a7a0-e823d40d7ca4","slug":"seborrhoeic-dermatitis-face-body","fullItemName":"Scenario: Seborrhoeic dermatitis - face and body"},{"id":"715da1f8-f458-5eec-96e8-85e22060d505","slug":"seborrhoeic-dermatitis-severe-or-widespread","fullItemName":"Scenario: Seborrhoeic dermatitis - severe or widespread"}]},{"id":"bac53cb4-0b97-5d4b-8ce4-07a9584a5e4f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"970b1e50-a3fc-503d-bbe8-29ecfa575d20","slug":"products-available-otc","fullItemName":"Products available OTC"},{"id":"9b1c8434-e7ce-5cd0-8c49-9e1076fbcecb","slug":"topical-imidazoles","fullItemName":"Topical imidazoles"},{"id":"d35c5c70-d96b-5a9a-a708-2e051cf3cece","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"}]},{"id":"b5cb8438-116a-5790-9b0f-2a480c577056","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"03823e51-3fec-53db-8dde-3fbe6e94526c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"364fda13-808d-599d-84cd-2b31ed7d0d94","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"fd9a5e23-6ee9-503f-bbc4-7239d8555e0e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1120e62a-fd06-536e-8caf-945332e36549","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"214850c4-e7af-5924-9a63-09325facd062","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"bfa9b404-d181-55eb-a3b2-8da0ee4edb43","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5171db55-6873-590e-b670-2d66a4b1b1eb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5f9559ed-2d1c-52f3-ae50-cb983d1b7c7c","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}